Mass spectrometry imaging (MSI) is increasingly being used as a label free method of evaluating the distribution of drugs and endogenous compounds in tissues. The technology has been welcomed by drug researchers eager to perform drug distribution studies at an earlier stage in the discovery timeline. The technology however is not limited to drug distribution studies but can also be used to detect a wide range of chemical species rendering it applicable to both pharmacokinetic and pharmacodynamic endpoints. Traditionally MSI has been used in a qualitative capacity, however it is increasingly being used for quantitative assessments of drug levels in tissue sections.
Introduction
Oncology is a growing research area in pharmaceutical R&D. The complex nature of cancer has prompted research into many potentially therapeutic pathways targeting changes in cancer cell growth, division, proliforation and death, making the space highly competitive and congested. In the search for ever more novel approaches in the fight against cancer researchers have now begun to focus on ways to make the body's own immune system specifically target cancer cells, an area known as immuno-oncology.
A common difference between tumor cells and normally differentiated cells is a change in cellular metabolism. Otto Warburg documented the classic metabolic shift of cancer cells to aerobic glycolysis, higher energy production and increased lactate concentration 1 hypoxia or other mechanisms promotes glycolysis and increases concentrations of suppressive metabolites and acidification of the local environment. As a by-product of glycolysis, lactate concentration increases, which is co-ordinately utilized by tumor cells to fuel their metabolism, promote macrophage polarization, and directly suppresses T cell function 4 .
Kreutz and colleagues (Brand et al., 2016) reported a novel mechanism whereby lactic acid produced by highly glycolytic tumors overcomes immune surveillance, by impairing activation of infiltrating cytotoxic CD8+ T and NK cells 5 .
Developing therapeutic approaches to modify T cells to utilize lactate as an energy and biomolecule source, similar to the pathways operating in some tumor cells, or reducing the levels of lactate in the micro-environment may provide means to overcome this hurdle for tumor immunity.
Analytical methodologies that enable quantitative evaluation of tumor lactate levels in the tumor microenvironment are critical when developing potential new treatments. Furthermore, given the complex and heterogenic tumor architecture, spatial information of tumor lactate levels can provide valuable information to better understand both the endogenous distribution of tumor lactate and also the effects on endogenous levels after drug dosing in animal model efficacy testing. This understanding can then enable reliable pharmacokineticpharmacodynamic (PK-PD) understanding of the modulation of tumor lactate levels and how they correlate with overall effects on tumor growth.
Drug discovery is a lengthy, costly and competitive business. Potential new drugs can take more than ten years to reach commercialization, at a cost of billions of dollars. Furthermore, attrition rates during the later stages of development increase the already high risk factors involved with taking a new compound into the clinic 6 . Pharmaceutical companies have gone to great lengths to decrease these high failure rates, minimising risk in an effort to maximize reward and bring new medicines to the market 7 . Poor efficacy and toxicity are the main reasons for high attrition rates within research and development (R&D) 8 . The industry has addressed this problem by adopting a strategy of early, accelerated compound optimisation with parallel generation of physicochemical and pharmacokinetic properties to design safer and more efficacious drug candidates that maximize therapeutic index whilst minimising any risk of toxicity 9 .
Bioanalytical techniques such as LC-MS have kept pace with the need for higher throughput 10 but are limited in value when trying to assess a drug's distribution in vivo. Traditionally drug distribution studies were performed during the later stages of development using radiolabelled compounds in low throughput techniques such as qWBA 11 or homogenization 12 studies using LC-MS with long liquid chromatography gradients. Mass spectrometry imaging (MSI) is a term given to a group of label free, multiplex analytical techniques that can essentially map the molecular distribution of endogenous compounds, drugs 13 , lipids 14 , proteins 15 , peptides 16 and drug delivery systems 17 in biological tissues. MSI techniques are all based on different mass spectrometry surface sampling ion sources of which matrix assisted laser desorption ionization mass spectrometry imaging (MALDI-MSI) 18 has arguably the most widespread use within the pharmaceutical industry. MALDI-MSI is being rapidly joined by other MSI techniques such as desorption electrospray ionization mass spectrometry imaging (DESI-MSI) 19 and liquid extraction surface analysis mass spectrometry imaging (LESA-MSI) 20 that bring complementary properties such as an expanded chemical scope and increased sensitivity, usually at the expense of decreased spatial resolution. Essentially, each technique rasters or continuously scans across tissue sections acquiring a constant full mass spectrum at each pixel or coordinate, each mass signal within the spectrum is assigned an intensity that can then be color coded into a heat map image describing the relative abundance of an analyte within the tissue.
Whilst not replacing traditional bioanalysis, MSI is increasingly being used alongside these techniques providing timely and cost effective insights into the deposition and fate of new chemical entities 21 . The application of the technique has been expanded further to encompass endogenous compound changes as markers for drug induced efficacy 22 or toxicity 23 .
Applications of MSI within the drug discovery industry are well documented 24 . It has increasingly been used to provide molecular distribution information at an early stage of the drug development pipeline. Several groups have reported successful imaging of low mass endogenous metabolites in tumors 25 . Data has largely been qualitative in nature but in order to expand the applicability of MALDI-MSI into pharmacodynamic testing of compound efficacy, quantitative mass spectrometry imaging (qMSI) methods are needed that can spatially resolve regions of high abundance in what is often complex tumor architecture.
Here we present a mass spectrometry imaging methodology for the absolute quantitation of two key endogenous metabolites involved in tumor cell energy production (glycolysis and the TCA cycle), lactate and glutamate. The techniques developed were used to screen several mouse tumor models to identify a suitable phenotype to reliably monitor lactate changes post drug administration in efficacy studies. We also present regiospecific quantitation post spectral segmentation to highlight the heterogeneity of each tumor model.
Methods

Materials and reagents
Analytical grade acetonitrile, methanol and formic acid were obtained from Fisher Scientific (Loughborough, Leicestershire, UK). 2-methylbutane, gelatin, lactate-13 C3, lactate 13 C1, Glutamate-D3, 1, 5-diaminonaphthalene and 9-aminoacridine were purchased from Sigma-Aldrich (Poole, Dorset, UK). Test compound for the efficacy study was obtained inhouse from AstraZeneca compound management group (Macclesfield, Cheshire, UK).
Lactate-13 C1 and Glutamate-D5 were purchased from QMX Laboratories (Thaxted, Essex, UK).
Amino acid stability in rat kidney sections
Duplicate control kidney sections (10µm) were cut and mounted onto glass microscope slides over a 24h time-course (0, 0.5, 18, 21 & 24h). Sections were stored at one of three different conditions between time-points; (1) left in the cryostat thaw mounted at -16ºC, (2) thaw mounted, dessicated in N 2 , vacuum packed and stored at ambient temperature, or (3) thaw mounted, dessicated in N 2 , vacuum packed and stored at -80ºC. A 'fresh' kidney section was mounted on each slide prior to analysis by desorption electrospray mass spectrometry imaging.
Animals studies
All animal studies were conducted in accordance with UK Home Office legislation, the Animal Scientific Procedures Act 1986, and the AstraZeneca Global Bioethics policy. All experimental work is outlined in home office license 40/8894, which has gone through the AstraZeneca Ethical Review Process.
Initial proof of priciple study (AZx)
AZx was dosed at 3 dose levels (3, 30 and 100 mg/kg) to athymic nude mice from a NCI-H358 tumor model over an 8 day period. Five animals from each dose level were sacrificed at 0.5, 2, 6 and 24 h post dose. Five time-matched vehicle dosed animals at each dose level were also euthanized to act as a direct comparison. All tumors were resected at necropsy and snap frozen in dry ice chilled 2-methyl butane. The tumors were stored at -80°C prior to cryosectioning and subsequent analysis.
Mouse models (Screening)
Four different female athymic nude mice tumor models were screened for lactate and glutamate concentration and distribution. The four models tested were NCI-H358 (a human xenograft model grown in nude mice), MC38, B16.F10.AP3 and a MC38 Variant (all syngeneic mouse tumor models)
Tissue Embedding
Tissue embedding methodology can be found in the supplementary information.
Sectioning
Details of the methodology used in cryosectioning the tissues used in this study can be found in the supplementary information.
DESI mass spectrometry imaging
Details of the DESI-MSI method used in the stability experiments can be found in the supplementary information.
Lactate calibration standard preparation
Three stock solutions of Sodium L-lactate-13 C3 solution (Sigma-Aldrich, 485926-500MG) were prepared daily as needed at concentrations of 500, 5000 and 50000 µM in 50/50 v/v Methanol/Water. A sample of blank 50/50 v/v methanol/water was also retained.
Calibration spots for quantitation were added to control tissue sections (on each day of analysis) using a Preddator robotic liquid handler (Redd and Whyte, London, UK), at amounts equal to 0, 10, 25, 50, 100, 250 and 500 ng of lactate on-tissue. The liquid handler dispensed 50 nL droplets of the standards and over spotting in a total of 4 cycles to reach the required on-tissue amounts of the analyte. Spots were allowed to dry at room temperature prior to matrix addition.
Glutamate calibration standard preparation
Stock solutions of D3-glutamate and D5-glutamate were prepared daily at 100 mM in 0.1 M HCl. D5-glutamate standards were prepared by dilution in 50 % EtOH to concentrations of 2 mM, 0.67 mm, 0.22 mM, 0.074 mM, and 0.025 mM. 0.1 µl of the standards and a blank sample (50% EtOH) were manually applied to control tissue. D5-glutamate was used as an internal standard. 50 µl of the stock solution was added to 5.95 ml of 50% MeOH and sprayed onto the tissue before matrix application application using a TM-sprayer (HTX technologies, Chapel Hill, NC, USA) with the following parameters; 6 passes at 90°C using a flow 50% methanol/water v/v at a flow rate of 0.07 mL/min and nebulized with nitrogen at 6 psi.
MALDI Matrix Application
Details of automated matrix application methods for lactate and glutamate analysis can be found in supplementary information.
MALDI Quantative Mass Spectrometry Imaging (qMSI)
MALDI-MSI experiments were carried out in negative reflectron mode over a mass range of 
Spectral Clustering Analysis
Data were imported into Matlab (version R2017a and statistics toolbox, The Math-Works, Inc., Natick, MA, USA) using SpectralAnalysis version 1.01 27 . Briefly, a mean spectrum was generated for each dataset, which was peak picked using the SpectralAnalysis gradient peak picking. These peaks were then extracted into a datacube by integrating under the area for each peak. Data were then normalised to the 13 C lactate or glutamate peak (nominally m/z 90.028 and 147.048). These lactate and glutamate concentrations were then quantified to the calibration curves generated from spots applied to a separate tissue section. Clustering was then performed on each of the individual tissue sections using k-means clustering with k = 2-5 (k = 4 shown), using the cosine distance metric 28 . Boxplots of lactate and glutamate concentration were generated using the Matlab function "boxplot" where the central line shows the median concentration, the box represents the 25-75% interquartile range of the data and the whiskers are one additional interquartile range above and below these. Any points outside this range are considered outliers marked by red crosses.
Homogenization and Quantitation of Lactate Levels by LC-MS
Details of the homogenization and LC-MS method can be found in the supplementary information.
Results and Discussion
Endogenous Amino Acid Stability Experiment
Previous in-house experience of endogenous metabolite analysis using DESI-MSI had suggested that degradation of endogenous lactate within rat kidney tissue during sample preparation (data not reported) was possible. This ex-vivo change in endogenous small molecule levels was found to be related to the amount of time the tissues spent in the -20°C environment of the cryomicrotome during the sectioning process and appeared to stabilize during analysis when the sample is removed from the freezer and effectively kept in a desiccated nitrogen rich environment on the DESI stage. Prior to embarking on a quantitative study of lactate and glutamate concentrations in different tumor models it was thus necessary to establish a protocol to stabilize or make sure any degradation of the endogenous compounds within the tissues was as uniform as possible. Kidney sections were taken over a time course spanning 24h in total, the resulting sections were stored between time-points in one of three different conditions; (1) left in the cryostat thaw mounted at -16ºC, (2) thaw mounted, desiccated in N 2 , vacuum packed and stored at room temperature, or (3) (1) and (2) and 42713 and 12094 in the medullary regions. Glu, Asp and glut levels were also found to be more stable under conditions (3) with corresponding improvements in δ values. These results highlighted the need for -80ºC storage, even over a short period of time.
Interpreting the results further, it was clear that immediate desiccation post sectioning followed by vacuum packing and storage at -80ºC was needed to minimize the degradation of the endogenous metabolites in the tissue, however even with this safeguard, instability could still occur as multiple sections were cut one at a time onto the same microscope slide within the cryostat. To minimize the amount of time sections were kept in the cryostat chamber it was decided to embed multiple tissues in gelatin and section them all in a single cut of the microtome blade. This significantly reduces the amount of time the sections spend at temperatures higher than -20°C, with the added bonus of reduced sample preparation time.
The embed, thaw mount, desiccate, vaccum pack and store at -80°C protocol was thus adopted for all subsequent analysis.
Initial proof of principle
In order to test the hypothesis that it was possible to quantify and map the spatial distribution of lactate in tumor tissue using qMSI, an initial study was performed in a NCI-H358 human xenograft mouse tumor model. Animals were treated with a proprietary drug (AZx) that is known to induce changes in tumor metabolism. Lactate distribution and concentration levels from tumors treated with AZx were compared to vehicle dosed control animals. Although DESI-MSI had been used in the initial stability experiments it was decided to proceed with a more validated quantitative imaging platform, MALDI-qMSI was thus used to map and quantify the lactate distribution within the tumor tissue. Due to the unavailability of a second stable-labelled version of lactate this analysis was performed with normalization to total ion current. The results from the analysis (Figure 2) showed that lactate changes could be observed in the tumor tissue after exposure with AZx. The analytical method performed well giving a linear response (R 2 = 0.997) across the calibration range (Figure 2b) contrast to lactate which was much more heterogeneously distributed and localized into the necrotic or pre-necrotic regions (identified using H&E staining) of the tissue. Glutamate levels in these lactate rich regions were much lower than those observed in the surrounding tissue giving a visual representation of the 'Warburg effect'.
Tumor model screening
The heterogeneous lactate distribution in the NCI-H358 tumor model used in the initial study had been shown to lead to high inter-tumor variation in lactate levels. This could be due to several factors including the tumor model itself and the duration at which the tumors are allowed to mature. High inter-animal variation decreases the likelihood of detecting subtle differences in endogenous amino acid levels in the dosed animals compared to vehicle treated animals, this could be the reason that no lactate modulation was observed in the early and late timepoints of the initial study. A tumor model that exhibits a more homogeneous lactate distribution would be highly desirable and should reduce the inter-tumor variability giving a more robust model to move forward into efficacy testing and ultimately build a reliable PK/PD model. Several different tumor models were selected for lactate screening. An NCI- 
Conclusion
Early confirmation of drug efficacy in humans is of great value to drug discovery projects.
Cellular or enzymatic assays can be used to determine compound potency but are rarely a substitute for in vivo experiments in syngeneic preclinical animal models. Determination of efficacy endpoints that are directly related to the target pathway in the form of endogenous metabolite differences in diseased human tissue is a gold standard. Thiscan however be misleading in complex tissue environments such as tumor tissue due to localization of the metabolites into different tissue compartments within the tumor.
Here we have established sample pre-treatment protocols that minimize the degradation of endogenous amino acids within sectioned tissue, all tissues are handled in a standardized way and stored under the same conditions to ensure any degradation that does occur is uniform across all sections in the same experiment.
We have demonstrated that the spatial resolution MSI can offer can be successfully used to assess the distribution of endogenous metabolites within different tumor models. We have also shown that MALDI-MSI can be used as a quantitative technique to measure the absolute concentration of these metabolites in situ, furthermore, we have shown how spectral clustering can be used to generate regio-specific concentration data within the tumor sections to give a more empirical illustration of tumor heterogeneity.
Quantitative MSI methods such as those reported in this work can be expanded in the future.
The multiplex nature of qMSI methods could allow simultaneous quantitation of several endogenous compounds in the same tissue section, it can also be used to encompase different endogenous compound classes such as lipids, peptides and proteins that can modulate with disease state and give evidence of target engagement or drug efficacy in many other potential therapeutic targets. The boxplots show the differencing heterogeneity of the concentrations of lactate or glutamate based on the different tumour models. The MC38 variant and NCI-H358 tumours have more homogeneously distributed lactate concentration compared to the B15F10 and MC38 models, glutamate concentration is more homogeneous than lactate in all of the models.
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